

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Description: Insulin Degludec (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Insulin Degludec (Type 2 Diabetes) – Analysis and Forecasts to 2020" provides Insulin Degludec sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Insulin Degludec
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Insulin Degludec including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2013-2020 for Insulin Degludec in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Insulin Degludec, Type 2 Diabetes, Diabetes, Sales forecast, ultra long acting insulin, Phase III, Phase 3, Pipeline, Lantus, Levemir, Novo Nordisk

Contents:	1
	1
	1.1 List of Tables
	1.2 List of Figures
	2 Introduction
	2.1 Diabetes
	2.2 Epidemiology
	2.2.1 Prevalence
	2.2.2 Mortality
	2.3 Etiology and Risk Factors
	2.3.1 Obesity
	2.3.2 Sedentary Lifestyle
	2.3.3 Family History and Genetics
	2.3.4 Ethnicity
	2.3.5 Old Age
	2.4 Economic Impact of Diabetes

- 2.5 GlobalData Report Guidance
- 3 Type 2 Diabetes: Market Characterization
 - 3.1 Type 2 Diabetes Market
 - 3.2 Type 2 Diabetes Market Forecasts and CAGR
 - 3.3 Type 2 Diabetes Market: Drivers and Restraints
 - 3.3.1 Drivers
 - 3.3.2 Restraints
- 4 Classification of Diabetes
 - 4.1 Types of Diabetes
 - 4.1.1 Type1 Diabetes
 - 4.1.2 Type 2 Diabetes
 - 4.1.3 Gestational Diabetes
 - 4.2 Diabetes Complications
 - 4.2.1 Cardiovascular Disease
 - 4.2.2 Nephropathy
 - 4.2.3 Neuropathy
 - 4.2.4 Amputation
 - 4.2.5 Retinopathy
- 5 Evolution of Anti-Diabetic Treatments
- 6 Medications
 - 6.1 Insulin
 - 6.2 Oral Medications
 - 6.2.1 Sulfonylureas (SUR)
 - 6.2.2 Biguanides (BGDs)
 - 6.2.3 Alpha-Glucosidase Inhibitors (AGI)
 - 6.2.4 Meglitinides
 - 6.2.5 Thiazolidinediones (TZDs)
 - 6.2.6 Dipeptidyl Peptidase IV (DPP-4) Inhibitors
 - 6.2.7 Oral Combination Therapy
 - 6.3 Other Injectionable Medications
 - 6.3.1 Pramlintide
 - 6.3.2 Exenatide
 - 6.4 Market Share as per Classes in Type 2 Diabetes
- 7 Insulin Degludec
 - 7.1 Introduction
 - 7.2 Mechanism of Action
 - 7.3 Clinical Studies
 - 7.4 Factors Affecting Sales of Insulin Degludec
 - 7.4.1 Novel Ultra Long-Acting Insulin
 - 7.4.2 Growing Insulin Market
 - 7.4.3 Higher Dosing Convenience
 - 7.4.4 Reduced Incidence of Hypoglycemia
 - 7.5 Drug Evaluation
 - 7.5.1 Drug Risk Benefit Score
 - 7.5.2 Intensity of Competition
 - 7.6 Sales Forecasts
 - 7.6.1 Target Patient Pool
 - 7.6.2 Dosing
 - 7.6.3 Annual Cost of Therapy
 - 7.6.4 Market Penetration
 - 7.6.5 Sales Projections of Insulin Degludec
- 8 Diabetes Market: Appendix
 - 8.1 Market Definitions
 - 8.2 List of Abberiviations
 - 8.3 Research Methodology
 - 8.3.1 Coverage
 - 8.3.2 Secondary Research
 - 8.3.3 Forecasting
 - 8.3.4 Number of patients approved to take the drug
 - 8.3.5 Net Penetration of Drug
 - 8.3.6 Net Annual Dosing
 - 8.3.7 Annual Cost of Therapy
 - 8.4 Drug Sales Estimates Model

8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures (\$m), 2010
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
Table 8: Diabetes Drugs Evolution
Table 9: Drug Risk Benefit Score of Insulin Degludec
Table 10: Types of Insulin
Table 11: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2013-2020
Table 12: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2013-2020
Table 13: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2013-2020
Table 14: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts (\$m), 2013-2020
Table 15: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2013-2020
Table 16: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2013-2020
Table 17: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2013-2020
Table 18: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2014-2020

1.2 List of Figures

Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030
Figure 3: Diabetes, World, Mortality, 2010
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts (\$bn), 2010-2020
Figure 6: Mechanism of Action of Sulfonylureas
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
Figure 9: Mechanism of Action of Thiazolidinediones
Figure 10: Mechanism of Action of DPP IV Inhibitors
Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010
Figure 12: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts (\$m), 2013-2020
Figure 13: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts (\$m), 2013-2020
Figure 14: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts (\$m), 2013-2020
Figure 15: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts (\$m), 2013-2020
Figure 16: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts (\$m), 2013-2020
Figure 17: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts (\$m), 2013-2020
Figure 18: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts (\$m), 2013-2020
Figure 19: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts (\$m), 2014-2020
Figure 20: Insulin Degludec, Type 2 Diabetes, Sales Distribution by Country (%), 2020
Figure 21: Patients Approved for the Drug

Ordering: Order Online - <http://www.researchandmarkets.com/reports/2075322/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020
Web Address: <http://www.researchandmarkets.com/reports/2075322/>
Office Code: SCUUPCZK

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 3260
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 1630
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 4890

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVW Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World